Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 16/20 | 0.45 |
| ▸ | HTR2C | P28335 | 16/20 | 0.45 |
| ▸ | HTR2B | P41595 | 16/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21745068 | 0.96 | HTR2A (0.44) | HTR2AHTR2CHTR2BMEN1GAA | |
| SCHEMBL21745067 | 0.96 | HTR2A (0.44) | HTR2AHTR2CHTR2BMEN1GAA | |
| SCHEMBL21745496 | 0.96 | HTR2A (0.44) | HTR2AHTR2CHTR2BMEN1GAA | |
| SCHEMBL21762403 | 0.92 | HTR2A (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL21762803 | 0.92 | HTR2A (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL21745502 | 0.80 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL21745501 | 0.80 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL21745108 | 0.80 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL21762794 | 0.77 | GAA (0.56) | HTR2AHTR2CHTR2BMEN1GAA | |
| SCHEMBL21745144 | 0.77 | GAA (0.56) | HTR2AHTR2CHTR2BMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2020041169-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-27 | — | — | WO | disclosed |